Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$100.32 ▲ +0.22
(+0.22%)
MKT CAP: $6.55B • VOL: 771.7K
52W L $50 52W H $112
LNTH // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.54B | $1.53B | $1.30B |
| YoY Revenue Growth % | +0.5% | +18.3% | — |
| Gross Profit | $942.0M | $988.3M | $570.4M |
| Gross Margin % | 61.1% | 64.4% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $310.8M | $457.0M | $364.6M |
| Operating Margin % | 20.2% | 29.8% | 28.1% |
| Net Income (GAAP) | $233.6M | $312.4M | $326.7M |
| EBITDA (Normalized) | $366.3M | $512.2M | $411.3M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $390.1M | $544.8M | $305.3M |
| Capital Expenditures (CapEx) | $69.4M | $69.0M | $58.3M |
| Free Cash Flow (FCF) | $320.8M | $475.7M | $246.9M |
| FCF Margin % | 20.8% | 31.0% | 19.0% |
| Return on Invested Capital (ROIC %) | 19.8% | 62.6% | 13.2% |
| Cash & Short-Term Equivalents | $359.1M | $912.8M | $396.2M |
| Total Debt (Short + Long Term) | $511.9M | $401.5M | $842.7M |
| Total Stockholders' Equity | $1.09B | $1.09B | $1.73B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LNTH.